Interconnectedness of Factors Affecting Patient Willingness to Discuss Prostate Cancer Clinical Trials With Physicians

PURPOSE Racial disparities in prostate cancer clinical trial participation persist. Sociodemographic and psychosocial predictors of willingness to discuss trials are often studied in separate models that do not account for intercorrelations. Using consent-time data from the Partnering Around Cancer Clinical Trials (PACCT) study (ClinicalTrials.gov identifier: NCT02906241 ), we examined multidimensional group-based medical mistrust (GBMM) and related factors within one structural equation model (SEM). METHODS We conducted a cross-sectional secondary analysis of patient-reported data at consent from 286 Black and White men with prostate cancer enrolled in PACCT phases I and II (November 2016-February 2021) at two National Cancer Institute-designated centers. Willingness and general trust in physicians were observed variables; GBMM was a latent construct (suspicion, disparities, lack of support subscales). Models used robust maximum likelihood in lavaan (239 of 286 with complete SEM data). RESULTS Higher GBMM (β = −.247; P = .028) and older age (β = −.217; P = .004) were associated with lower willingness; higher education (β = .176; P = .019) was associated with higher willingness. Black ( v White) race was associated with higher GBMM (β = .555; P < .001) and had a significant indirect association with willingness through GBMM (β = −.137; P = .035), not a significant direct path. Higher income was associated with greater GBMM (β = .221; P = .020) and lower physician trust (β = −.268; P = .002) but not with willingness. CONCLUSION Willingness to discuss trials reflected an interconnected pattern in which multidimensional GBMM was central. Findings are exploratory and associational and support patient-centered trial communication where mistrust may be salient, tailored discussions for older patients, and accessible information where comprehension needs may apply. Longitudinal evaluation of PACCT interventions is needed.

Authors

Institutions

Publication Details

Journal
JCO Oncology Practice
Published
2026-08-24
DOI
https://doi.org/10.1200/op-26-00036
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Interconnectedness of Factors Affecting Patient Willingness to Discuss Prostate Cancer Clinical Trials With Physicians

Elisabeth I. Heath, Michael A. Carducci, Mark Manning, Janaka S. S. Liyanage et al.
JCO Oncology Practice
Ethics in Clinical Research
article

Interconnectedness of Factors Affecting Patient Willingness to Discuss Prostate Cancer Clinical Trials With Physicians

Elisabeth I. Heath, Michael A. Carducci, Mark Manning, Janaka S. S. Liyanage, Dina Lansey, Terrance L. Albrecht, Tanina Foster Moore, Susan Eggly, Lauren M. Hamel, Seongho Kim, Vy Ong
article en

Abstract

PURPOSE Racial disparities in prostate cancer clinical trial participation persist. Sociodemographic and psychosocial predictors of willingness to discuss trials are often studied in separate models that do not account for intercorrelations. Using consent-time data from the Partnering Around Cancer Clinical Trials (PACCT) study (ClinicalTrials.gov identifier: NCT02906241 ), we examined multidimensional group-based medical mistrust (GBMM) and related factors within one structural equation model (SEM). METHODS We conducted a cross-sectional secondary analysis of patient-reported data at consent from 286 Black and White men with prostate cancer enrolled in PACCT phases I and II (November 2016-February 2021) at two National Cancer Institute-designated centers. Willingness and general trust in physicians were observed variables; GBMM was a latent construct (suspicion, disparities, lack of support subscales). Models used robust maximum likelihood in lavaan (239 of 286 with complete SEM data). RESULTS Higher GBMM (β = −.247; P = .028) and older age (β = −.217; P = .004) were associated with lower willingness; higher education (β = .176; P = .019) was associated with higher willingness. Black ( v White) race was associated with higher GBMM (β = .555; P < .001) and had a significant indirect association with willingness through GBMM (β = −.137; P = .035), not a significant direct path. Higher income was associated with greater GBMM (β = .221; P = .020) and lower physician trust (β = −.268; P = .002) but not with willingness. CONCLUSION Willingness to discuss trials reflected an interconnected pattern in which multidimensional GBMM was central. Findings are exploratory and associational and support patient-centered trial communication where mistrust may be salient, tailored discussions for older patients, and accessible information where comprehension needs may apply. Longitudinal evaluation of PACCT interventions is needed.

JCO Oncology Practice
Oakland University (US), Wayne State University (US), The Barbara Ann Karmanos Cancer Institute (US), Sidney Kimmel Comprehensive Cancer Center (US)
No poverty
Openalex Percentile: Top 8%
Ethics in Clinical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.